Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$4.20
-$0.06(-1.43%)
At close: 4:00 PM EDT
$4.20
-$0.06(-1.43%)
Day’s Range― - ―
52-Week Range$1.39 - $27.15
Previous CloseN/A
Volume17.00K
Average Volume (3M)182.02K
Market Cap
$25.70M
Enterprise Value$28.67
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.64
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding17,485,462
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$80.00Price Target Upside1804.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA RMAT Designation Supports Allocetra DevelopmentRMAT status reflects supportive early clinical data and enables enhanced FDA engagement, potentially shortening development timelines and improving regulatory clarity as the 182-patient Phase IIb trial advances.
Planned Private Placement Could Strengthen FundingIf completed, the financing could provide substantial resources for Allocetra development and debt repayment, extending the company’s funding runway and reducing near-term dependence on repeated capital raises.
Very Low Leverage Limits Balance-sheet Interest RiskMinimal leverage reduces fixed financial obligations and interest-related pressure compared with more highly indebted biotechs, preserving some flexibility to allocate capital toward clinical development and regulatory activities.
Bears Say
No Established Product Revenue Or Operating TractionThe absence of recurring product revenue leaves the business dependent on clinical success, approvals and future commercialization, while persistent operating losses provide no evidence yet of a self-sustaining commercial model.
Persistent Cash Burn Creates Financing DependenceContinued negative operating and free cash flow means Enlivex must rely on external financing until its programs generate revenue, exposing shareholders to funding risk and potential dilution across the development cycle.
Debt Restructuring Raises Repayment And Dilution RiskLower monthly payments ease immediate liquidity pressure, but the higher principal, conditional interest and holder-friendly conversion terms can increase long-term financing costs and the risk of substantial equity dilution.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.39 and its highest was $27.15 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $25.70M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 241 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 17,485,462 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went down -0.38%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Stock 12 Month Forecast
Average Price Target
$80.00
▲(1804.76% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.18% Mutual Funds
― Other Institutional Investors
99.82% Public Companies and
Individual Investors